MDGL Q4 2017 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MDGLMadrigal Pharmaceuticals, Inc.

$10B

Q4 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$60,000

Operating Income

-$9M

Net Income

-$8M

EPS (Diluted)

$-0.67

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$6M

Stock-Based Comp.

$947,000

Balance Sheet

Total Assets

$192M

Total Liabilities

$10M

Stockholders' Equity

$182M

Cash & Equivalents

$149M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$60,000	$0	—
Operating Income	-$9M	-$8M	-16.0%
Net Income	-$8M	-$8M	-9.0%